SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.51-1.3%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (7575)12/20/2002 8:13:56 PM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
Harry,

First thanks for respond on Rick's questions.

Regards the Ocinaplon and Bicifadine IP right I share Peter’s view.

Ocinaplon: Time release formulation can be develop in many ways. ELN has patent protected nanotechnology/controlled-release technology in their formulation, but generic only need to show in pharmacokinetic trial that their formulation is bio-equivalent. Patent for O mechanism? This is new and hope it works.

Bicifadine: <<They have filed for patent on the crystalline structure of bicifadine--and say that any alternate stucture immediately degrades to their's, thus infringing on their patent-pending. (similar to structure strategy successfully used by NBIX on Indiplon)>>

If crystalline form is necessary for dosage formulation and to prepare specific crystallinity one need to run process chemistry than it is valid claim. However, if other forms (alternate crystalline structures) spontaneously and immediately degrades to most stable form that is not valid invention. NBIX IP strength is not in crystalline structure, it is in composite patent. I spent +6 months searching old Cyanamid-AHP patents and never identified Indoplon (by full structure) to be claimed.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News